Blue Cross Blue Shield — September 2026

emily_PDX said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

emily_PDX said:

...compounded vs brand cost and coverage...

This debate comes up weekly and I think both sides have valid points:

Pro-brand: FDA-approved, manufacturing standards guaranteed, clinical trial data directly applicable

Pro-compounded: 10x cost savings, same active molecule, independent testing available, accessibility

My position: if you can afford brand or have insurance coverage, that's the gold standard. If not, properly tested compounded from a 503B pharmacy is a reasonable alternative. Neither side should shame the other.

emily_PDX said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

Pushing back on emily_PDX here. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

Dr.NateNeph said:

The affordability discussion here usually stops at individual tactics.

Insurance update relevant to cost and coverage: I just got my prior auth approved through Aetna after 3 attempts.

What finally worked: a letter from my endocrinologist documenting BMI history (>3 years), failed diet attempts, comorbidities (sleep apnea + prediabetes), and referencing the SELECT trial data.

If your PA keeps getting denied, don't give up. Request a peer-to-peer review between your doctor and the insurance medical director. That's what finally broke through for me.

JennaRN said:

emily_PDX said: ...compounded vs brand cost and coverage...

Same pattern here, and in the same order. Posting only so the count is not one.